Novartis pays out for US biotech
February 17, 2014Research and Development, Sales and Marketing Cancer, Novartis, Vaccine, costim pharmaceuticals
Novartis is looking to shore up its cancer immunotherapy pipeline with the purchase of oncology specialist CoStim Pharmaceuticals. The Cambridge, …
Aveo and Astellas part ways
February 17, 2014Sales and Marketing Astellas, Aveo, Boehringer, EMA, tivozanib
Aveo Oncology and Astellas Pharma are to abandon their three-year old collaboration and licence agreement for investigational tyrosine kinase inhibitor …
NICE: new system will allow more drugs on NHS
February 17, 2014Sales and Marketing DH, Dillon, DoH, NHS, NICE, QALY
NICE has said that it will be able to approve more medicines under a new drug pricing policy, but warns …
Germany focus: strength with control
February 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMNOG, EFPIA, Germany, IQWIG, NHS, NICE
Germany is the biggest pharmaceutical market in Europe and one of the biggest in the world, but new systems and …
Shire chief financial officer steps down
February 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, hetherington
Shire’s chief financial officer (CFO) Graham Hetherington has notified the company of his decision to step down. Flemming Ornskov, Shire …
Pharma’s reputation ‘getting worse’
February 17, 2014Medical Communications, Sales and Marketing GSK, Gilead, Pfizer, ViiV, patientview, pharma, reputation
The pharma industry’s reputation is getting worse – at least, in the eyes of 800 patient groups – according to …
‘More than 2,000’ US lawsuits for Boehringer
February 14, 2014Sales and Marketing Boehringer, Pradaxa, Xarelto, blood thinner, warfarin
Boehringer Ingelheim is facing more than 2,000 lawsuits in the US over allegations that its stroke prevention pill Pradaxa has …
Former M&S chief executive to headhunt for NHS
February 14, 2014Medical Communications, Sales and Marketing Dalton, Hunt, NHS, stuart rose, superheads
Health secretary Jeremy Hunt has appointed the man accredited with turning around the fortunes of Marks and Spencer to advise …
Pfizer faces Australia action
February 14, 2014Medical Communications, Sales and Marketing Australia, Lipitor, Pfizer, accc
Pfizer has a legal battle on its hands in Australia, where the country’s consumer watchdog has begun proceedings in the …
Emperra appoints new chief executive
February 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing e-health, emperra, krey
Healthcare development firm Emperra E-Health Technologies has hired Dr Christian Krey as managing director and chief executive. Krey was previously …
Doctors highlight NHS data concerns
February 13, 2014Medical Communications, Sales and Marketing NHS, RGCP, UK, care data, doctors
Senior doctors have voiced their worries about the public’s lack of preparedness for the government’s planned roll-out of patient data …
FDA extends licence for Janssen’s Imbruvica
February 13, 2014Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia
Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …
Aesica hires director from Catalent
February 13, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aesica, Catalent, muir
Contract development and manufacturing organisation (CDMO) Aesica has appointed Ian Muir to the newly-created position of commercial managing director. Muir’s …
Kadcyla launches in UK
February 13, 2014Sales and Marketing CDF, Cancer, Kadcyla, NHS, Roche, breast
Roche’s Kadcyla, indicated to treat an aggressive form of breast cancer, has launched today in the UK.Kadcyla (trastuzumab emtansine) which …
NHS England savings ‘not used wisely’
February 12, 2014Sales and Marketing England, NHS, QIPP, Simon Stevens, health select
A group of influential MPs has raised serious concerns over what the £10 billion worth of NHS England savings made …
NICE: ‘Use more statins’
February 12, 2014Sales and Marketing NHS, NICE, baker, cvd, statins
NICE has decided more NHS patients ought to be considered at risk of cardiovascular disease (CVD) – and therefore advises …
ICR: ‘Pharma needs stronger incentives’
February 12, 2014Research and Development, Sales and Marketing ICR, cancer research, itcc, pharma, r and d
The pharma industry must be given greater monetary help to persuade it to develop drugs which are specifically for children, …
Teva under investigation for marketing practices
February 12, 2014Sales and Marketing Azilect, Copaxone, Teva, fines, generics
Teva Pharmaceuticals is under investigation by US authorities for sales and marketing activity around two of its drugs – including …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
